L-Carnosine

Research-Grade

L-Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide found at high concentrations in skeletal muscle (5-10 mM), cardiac muscle, and brain tissue. First discovered in 1900 by Vladimir Gulevich, carnosine is one of the most abundant small molecules in mammalian tissue and has been the subject of over 2,000 peer-reviewed publications investigating its biological roles and therapeutic potential. It is synthesized intracellularly by the enzyme carnosine synthase from beta-alanine and L-histidine, and is degraded by the zinc metalloprotease carnosinase (CN1 in serum, CN2 intracellularly). Carnosine's primary biological activities span four major categories. First, it is one of the most potent naturally occurring anti-glycation agents — it reacts with and neutralizes reactive carbonyl species (methylglyoxal, glyoxal, hydroxynonenal) and advanced glycation end products (AGEs) that cross-link proteins and contribute to the structural deterioration of collagen, lens crystallins, and other long-lived proteins during aging. Second, it functions as an intracellular pH buffer, maintaining optimal pH in actively contracting muscle (where lactic acid accumulation impairs performance) and in neurons during excitatory signaling. Third, it exhibits direct antioxidant activity through metal chelation (Cu2+, Zn2+), free radical scavenging, and protection of membrane lipids from peroxidation. Fourth, it modulates cellular senescence — the landmark studies by McFarland and Holliday (1994, 1999) demonstrated that carnosine extends the replicative lifespan of cultured human fibroblasts and reverses the senescent phenotype, findings that launched carnosine's reputation as a longevity molecule. The anti-glycation property is particularly significant for aging research. Glycation — the non-enzymatic reaction of sugars with proteins — is one of the fundamental molecular mechanisms of aging, contributing to arterial stiffness, kidney damage, lens opacification (cataracts), skin aging, and diabetic complications. By scavenging the reactive carbonyl intermediates that drive glycation, carnosine provides molecular-level protection against a broad class of age-related tissue damage. Carnosine levels decline with age (approximately 50% reduction by age 70), paralleling the acceleration of glycation-related pathology. Human supplementation studies have explored carnosine (typically 500-2000 mg/day orally) for athletic performance enhancement (as a precursor for muscle carnosine/pH buffering), diabetic nephropathy, autism spectrum disorder, cognitive decline, and cataract prevention. Beta-alanine supplementation is often preferred for raising muscle carnosine levels because beta-alanine is the rate-limiting precursor and bypasses the serum carnosinase that degrades oral carnosine. For systemic anti-glycation and anti-aging applications, direct carnosine supplementation is used despite partial serum degradation, as tissue-protective effects have been demonstrated in multiple clinical contexts.